21 research outputs found
Repositorio del trabajo "Dinámicas de colaboración científica en la Universidad Abdelmalek Essaadi: Perspectivas y Retos"
No full text<p>Este conjunto de datos comprende análisis detallados sobre la producción científica financiada de la Universidad Abdelmalek Essaadi (UAE), utilizando información extraída de la Web of Science y procesada a través de herramientas como VOSviewer. Incluye:</p>
<ol>
<li><strong>Co-author-Map.json</strong>: Un mapa de coautoría visualizando las redes de colaboración científica de la UAE, indicando patrones de cooperación internacional y doméstica.</li>
<li><strong>Co-occurrence-Map.json</strong>: Muestra la coocurrencia de palabras clave en documentos financiados, resaltando las principales áreas de investigación y su evolución.</li>
<li><strong>Incites Funding Agencies.csv</strong>: Un archivo CSV que detalla las agencias de financiación detrás de los documentos de la UAE, su origen geográfico y el impacto de su apoyo.</li>
<li><strong>Data from Web of Science funded documents (UAE).txt (2 documentos)</strong>: Texto que contiene datos crudos de los documentos financiados, incluyendo títulos, autores, resúmenes y métricas de impacto.</li>
</ol>
Detection and mitigation technique against collusion attack in RPL-Based IoT networks
No full textThe Internet of Things (IoT) is a technology used in applications varying from home- and industrial automation to medical devices, smart vehicles, fitness trackers and many more. Such IoT networks often consist of incredibly resource-constrained devices, and are known as Low-power and Lossy Networks (LLNs). The Routing Protocol for LLNs (RPL) aims to provide a routing standard for such networks. Due to the tough performance constraints, RPL is unable to provide strong security guarantees. Many researchers are posing attacks against RPL-based networks, and with the increasing number of implementing devices, it is important that research is done to ensure message integrity and network reliability. In this paper we concern ourselves specifically with collusion attacks. We propose Hop-Count Reachability (HCR), a mitigating method against the coordinated blackhole attack. In HCR, leaf nodes periodically ping the root node with DAO messages. If the root node is reachable, it will reply with a DAO-ACK, upon which the leaf node sleeps for a period of time. When the number of missed ACKs in a certain time frame exceeds a certain threshold, the affected node may identify the attack and mitigate it by selecting a new parent. HCR may increase control packet overhead anywhere between 1.6 and 25\% depending on the chosen parameters, and successfully mitigates the coordinated blackhole attack in all scenarios where affected nodes can choose an (eventually) unaffected parent.CSE3000 Research ProjectComputer Science and Engineerin
Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis
No full textPURPOSENeoadjuvant chemoimmunotherapy followed by adjuvant immunotherapy is the gold standard for treating patients with higher risk early triple-negative breast cancer (TNBC); however, in some cases, these patients undergo surgery followed by chemotherapy-based anthracyclines and taxanes without adhering to the guidelines.METHODSPatients with previously untreated stage I, II, and III TNBC who received adjuvant therapy with either doxorubicin and cyclophosphamide (AC) + docetaxel (AC-D), AC + weekly paclitaxel (AC-WP), epirubicin and cyclophosphamide (EC) + docetaxel (EC-D), or EC + WP (EC-WP); older than 18 years; and diagnosed between January 1st, 2011, and December 31st, 2022, were eligible for the study. Disease-free survival (DFS) is the primary reported end point. Overall survival (OS) and safety were the secondary end points.RESULTSWe included 272 female patients. At a prespecified event-driven data cutoff, with a median follow-up of 26.3 months, the 5-year DFS was 49% (95% CI, 38 to 63) in the AC-D group, 45% (95% CI, 29 to 70) in the AC-WP group, 73% (95% CI, 61 to 100) in the EC-D group, and 72% (95% CI, 44 to 100) in the EC-WP group (hazard ratio [HR], 0.2 [95% CI, 0.06 to 0.67]; P = .08). The 7-year OS was 52% (95% CI, 32 to 83) in the AC-D group, 88% (95% CI, 78 to 99) in the AC-WP group, 95% (95% CI, 88 to 100) in the EC-D group, and 83% (95% CI, 58 to 100) in the EC-WP group (HR, 0.19 [95% CI, 0.06 to 0.66]; P = .03). Most of the grade 3-4 adverse events occurred in the AC-D group, primarily neutropenia, nausea-vomiting, and alopecia.CONCLUSIONEC-D was linked to a slightly longer survival free of invasive, noninvasive, or distant disease and a significantly longer OS with fewer adverse events. Further studies are needed to confirm and establish long-term clinical benefits
Analyse des performances de l'indice boursier alternatif par rapport au MASI à l'aide du modèle GARCH
No full textInternational audiencePurpose: This paper aims at analyzing the performance of the alternative stock market index (SPMII) compared to its counterpart (MASI) by the S&P model.methodology: The study constructed over a period from 01/01/2017 to 12/31/2018. Using the Augmented Dickey Fuller (ADF) test to investigate the stationarity of the two stock market indices. Then, we estimated the average model for the ARCH effect by the ARCH-LM test and, by GARCH type models with the generalized error distribution (GED), as well as, forecasting their future variations by using the standard loss functions (symmetric) to evaluate the forecasting performance of competing models: (RMSE), (MAE), (MAPE) and (TIC).Findings: The curve of SPMII varies in a quasi-stable manner, unlike its counterpart which climbs significantly, given its date of birth, which is considered old, compared to the other which has just been created. The series of their returns show ARCH effects, which proves the impact of the heteroscedasticity effect. Table IV revealed that strong ARCH and GARCH effects are evident in the returns, inferring the appearance of a leverage effect. The results show that the EGARCH (1, 1) model outperforms all other models in predicting the volatility of (SPMII) and (MASI) returns. The results show that the SPMII is more stable due to its selection of less volatile companies, while the MASI exhibits greater volatility because of its age and the fluctuating performances of the companies. The volatility clustering effects and the leverage effect indicate a more pronounced response to negative shocks. Since the SPMII is recent, there could be unassessed temporal biases.Originality: This study compares, for the first time in Morocco, the performance of an Islamic stock market index (SPMII) with its traditional counterpart (MASI) using the Standard & Poor's model. It highlights the specific features of the Islamic index, its current and future fluctuations, and its potential as an investment alternative in the Moroccan financial market. We have noticed the absence of an Islamic stock index in Morocco. This has motivated us to design this index and study its performance. To date, the index has not yet been officially created on the Moroccan stock market. Governments should adopt favorable policies for Islamic indices and offer tax incentives to stimulate the market. Strengthen corporate transparency and governance to attract more capital. Encourage international cooperation to harmonize Islamic financial standards and widely integrate these indices.Objectif : Cet article vise à analyser la performance de l’indice alternatif du marché boursier (SPMII) par rapport à son homologue (MASI) à l’aide du modèle S&P.Méthodologie : L’étude couvre une période allant du 01/01/2017 au 31/12/2018. Elle utilise le test d’Augmented Dickey Fuller (ADF) pour examiner la stationnarité des deux indices boursiers. Ensuite, nous avons estimé le modèle moyen pour détecter l’effet ARCH à l’aide du test ARCH-LM, ainsi que des modèles de type GARCH avec une distribution d’erreur généralisée (GED). Par ailleurs, nous avons prévu leurs variations futures en utilisant les fonctions standard de perte (symétriques) pour évaluer les performances de prévision des modèles concurrents : RMSE, MAE, MAPE et TIC.Résultats : La courbe du SPMII varie de manière quasi-stable, contrairement à celle de son homologue qui connaît une montée significative, en raison de son ancienneté par rapport à l’autre, récemment créé. Les séries de leurs rendements présentent des effets ARCH, prouvant l’impact de l’effet d’hétéroscédasticité. Le tableau IV a révélé que de forts effets ARCH et GARCH sont évidents dans les rendements, indiquant l’apparition d’un effet de levier. Les résultats montrent que le modèle EGARCH (1, 1) surpasse tous les autres modèles dans la prévision de la volatilité des rendements du SPMII et du MASI. Les résultats montrent que le SPMII est plus stable grâce à sa sélection d'entreprises moins volatiles, tandis que le MASI présente une plus grande volatilité en raison de son ancienneté et des performances fluctuantes des entreprises. Les effets de regroupement de la volatilité et l'effet de levier indiquent une réponse plus marquée aux chocs négatifs. Le SPMII étant récent, il pourrait y avoir des biais temporels non évalués.Originalité : Cette étude compare, pour la première fois au Maroc, les performances d’un indice boursier islamique (SPMII) à son homologue traditionnel (MASI) en utilisant le modèle Standard & Poor's . Elle met en lumière les spécificités de l’indice islamique, ses fluctuations actuelles et futures, et son potentiel en tant qu’alternative d’investissement sur le marché financier marocain. Nous avons constaté l'absence d'un indice boursier islamique au Maroc. Cela nous a motivés à concevoir cet indice et à en étudier les performances. À ce jour, l'indice n'a pas encore été officiellement créé sur le marché boursier marocain. Les gouvernements devraient adopter des politiques favorables aux indices islamiques et offrir des incitations fiscales pour stimuler le marché. Renforcer la transparence et la gouvernance des entreprises cotées pour attirer plus de capitaux. Encourager la coopération internationale pour harmoniser les normes financières islamiques et intégrer ces indices largement
Anthroponymie chez Mohamed Nedali : du contact des langues aux contrastes sociaux
No full textMohamed Nedali is a contemporary Moroccan writer of French expression
born in 1962 in Tahannaout, about thirty kilometers from Marrakech where
he still lives. Having written eight novels with a realist vocation, he makes his region
his favorite place and fiction because, as he says in an interview, “in literature one only
speaks very well of a place one knows so well”. However, this attachment to space,
or at least this rootedness in identity that demonstrate the territorial anchoring of
the author, seems insufficient to serve his realistic vision. It is nevertheless true that
the intrusion of vernacular languages in a text written in a foreign language is not
without importance because it constitutes a significant element in a realistic fresco.
Indeed, the text of Nedali is strewn with Moroccan expressions. This intrusion is not
gratuitous and illustrates the role that the contact of languages can have in a fictional
narrative. Moreover, the choice of anthroponyms in Nedali’s fiction is not arbitrary,
as it is thoughtful and serves the author’s vision. Being a writer of soil and a good connoisseur
of the Moroccan society, the author uses it to create a fresco whose contrasts
illustrate his bias and his refusal of social evils
CNV-LDC: an optimised method for copy number variation discovery in low depth of coverage data
No full textRecent advances in sequencing technologies led to an increasing number of highly accurate ways of identifying and studying copy number variations (CNVs). Many methods and software packages have been developed for the detection of CNVs, generally these methods are based on four approaches: Assembly Based, Split Read, Read-Paired mapping and Read Depth. In this paper, we introduce an alternative method for detecting CNVs from short sequencing reads, CNV-LDC (Copy Number Variation-Low Depth of Coverage), that complements the existing method named CNV-TV (Copy Number Variation-Total Variation). To evaluate the performance of our method we compared it with some of the commonly used methods that are freely available and use different approaches to identify CNVs: Pindel, CNVnator and DELLY2. We used for this comparative study simulated data to gain control over deletions and duplications, then we used real data from the 1000 genome project to further test the quality of detected CNVs
Estimation of the cost of treatment by chemotherapy for early breast cancer in Morocco
No full textAbstract Background Breast cancer is the first cancer in women both in incidence and mortality. The treatment of breast cancer benefited from the progress of chemotherapy and targeted therapies, but there was a parallel increase in treatment costs. Despite a relatively high incidence of many sites of cancer, so far, there is no national register for this disease in Morocco. The main goal of this paper is to estimate the total cost of chemotherapy in the early stages of breast cancer due to its frequency and the chances of patients being cured. This study provides health decision-makers with a first estimate of costs and the opportunity to achieve the optimal use of available data to estimate the needs of antimitotics and trastuzumab in Morocco. Method We start by evaluating the individual cost according to the therapeutic sub-groups, namely: 1. Patients needing chemotherapy with only anthracycline-based therapy. 2. Patients needing chemotherapy with both anthracycline and taxane but without trastuzumab. 3. Patients needing trastuzumab in addition to chemotherapy. For each sub-group, the protocol of treatment is described, and the individual costs per unit, and for the whole cycle, are evaluated. Then we estimate the number of women suffering from breast cancer on the basis of two data bases available in Morocco. Finally, we calculate the total annual cost of treatment of breast cancer in Morocco. Results The total cost of breast cancer in Morocco is given in Moroccan dirhams (MAD), the US dollar at the current exchange rate (MAD 10 = USD 1.30) and in international dollars or purchasing power parity (MAD 10 = PPP 1.95). The cost of a therapy with trastuzumab is 8.4 times the cost of a sequential chemotherapy combining anthracycline and taxane, and nearly 60 times the cost of chemotherapy based on anthracycline alone. Globally, between USD 13.3 million and USD 28.6 million need to be devoted every year by the Moroccan health authorities to treat women with localized breast cancer in keeping with international recommendations. Discussion According to our estimation methods, the complete cost of adjuvant chemotherapy including trastuzumab will range from 1.3 to 2.4% of the global budget of the Moroccan Health Department (MAD 9.8 billion or USD 1.274 billion). Unfortunately, only one-third of the Moroccan population has healthcare insurance whereas for each patient the treatment with chemotherapy alone costs 1.15 times the annual minimum income (MAD 23,710 or USD 3,082), and treatment requiring both chemotherapy and trastuzumab costs 9.76 times the annual minimum income. For the tumour over expressing HER2Neu, we need to treat 25 women in order to save (cure) one woman: the calculated cost for one life saved is USD 663,000. The question is, is it cost-effective for an emerging country? Conclusion In this paper we aimed at evaluating the total cost of chemotherapy in the early stages of breast cancer in order to provide health decision-makers with a first estimation and a good opportunity for the optimal use of available data for the needs of antimitotics and trastuzumab in Morocco. Different protocols were considered and the individual cost of the whole treatment was given according to therapies using anthracycline alone, sequential chemotherapy combining anthracycline and taxane, and sequential chemotherapy with trastuzumab. According to our estimations, Moroccan health authorities need to devote between USD 13.3 million and USD 28.6 million every year in order to treat women suffering from localized breast cancer in ways consistent with international recommended standards.</p
Rural exodus and land use change in northern Morocco: 2000–2020
No full textThe implementation of the Urban Development Master Plan, SDAU (Schema Directeur d’Amenagement Urbain) in the Tangier-Tetouan region has marked a radical change in the territorial organization of these provinces: this process that began in 2004 with the construction of the port of Tanger-Med, and the infrastructures to support the port and related industrial areas. This action has meant the change of administrative boundaries as the project progressed. Although the demographic dynamics throughout the Kingdom of Morocco is a process of rural exodus, this migratory pattern is more intense in northern Morocco. The Andalusian Geographical Studies group of the University of Seville, together with Abdelmalek Essaadi University, has investigated the impact of such planning on spatial planning in a framework of international university cooperation since 2002. This article will update previous research based on remote sensing techniques and demographic statistics that analyze the changes that occurred over the last two decades. These changes consist of more than a massive displacement of the rural population toward the large cities and coastal towns. It also means the construction of large infrastructures, holiday houses, and a new pattern of settlement in rural areas. This article aims to describe these changes, as well as the trends in the immediate future, using statistical analysis and the evolution of land uses with GIS and remote sensing tools
Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort
No full textBackground: Doublet platin-chemotherapy was the old standard treatment for different histology types of advanced and metastatic lung cancer (LC) and is still an option for patients who are not eligible for immune checkpoint inhibitors. However, in low- and middle-income countries, chemotherapy, either in monotherapy or in combination with platinum, is still the only accessible option in public institutions. The efficacy of different platin-based chemotherapy in patients with LC who are treatment-naïve is unknown. Methods: In this retrospective study, we selected patients with advanced and metastatic (IIIB-IVB) non-squamous non-small cell LC (NSCLC), squamous NSCLC, and lung neuroendocrine tumours (small cell LC (SCLC), large cell neuroendocrine, and atypical carcinoid) aged beyond 18 years who received first-line chemotherapy (docetaxel, gemcitabine, etoposide, paclitaxel, pemetrexed, and vinorelbine) combined with platinum between January 1, 2013, and December 31, 2022. Within the population with non-squamous NSCLC, squamous NSCLC, and neuroendocrine tumours, progression-free survival (PFS) and overall survival (OS) were the primary assessed endpoints. Hematologic safety was the secondary endpoint. Results: Overall, 611 patients were included. In the group of patients with non-squamous NSCLC (n = 390), there was no statistical difference between subgroups of patients who received first-line platin-chemotherapy. The median PFS was 182 (95 % confidence interval [CI], 167–208) days (hazard ratio for progression: NR [Not Reached]; p = 0.37), and the median OS was 446 (95 % CI, 405–559) days (hazard ratio for death: 1.31; 95 % CI, 0.94 - 1.82; p = 0.1). In the group of patients with squamous NSCLC (n = 149), we note the absence of statistical significance between subgroups of patients who received platin-based chemotherapy. The median PFS was 195 (95 % CI, 142–238; hazard ratio for progression: 1.21, 95 % CI, 0.29–5.02; p = 0.27), while the median OS was 428 (95 % CI, 324–940) days (hazard ratio for death: 1.76; 95 % CI, 0.93 to 3.3; p = 0.32). The absence of significance has been noticed in the neuroendocrine subgroup of patients who received first etoposide-platinum, vinorelbine-platinum, or paclitaxel-platinum (n = 72). The median PFS was 216 (95 % CI, 193–277) days; hazard ratio for progression: 1.74, 95 % CI, 0.41–7.27; p = 0.69, while the median OS was 273 (95 % CI, 241–459) days (hazard ratio for death: 2.95; 95 % CI, 0.4–21.7; p = 0.51). Grade 3–4 neutropenia grade was the predominant adverse event associated with chemotherapy in almost 11 % of patients. Conclusion: Moving forward, treatment strategies must be refined for patients, with an emphasis on increasing the number of patients who can benefit from emergent approaches in order to guarantee a wider, deeper, and longer-lasting outcome
